Protalix BioTherapeutics (NYSE:PLX) Downgraded to “Buy” Rating by StockNews.com

Protalix BioTherapeutics (NYSE:PLX) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Friday.

Protalix BioTherapeutics Stock Down 2.8 %

Shares of Protalix BioTherapeutics stock traded down $0.07 during trading on Friday, hitting $2.46. 526,203 shares of the stock traded hands, compared to its average volume of 721,433. The stock has a market cap of $181.13 million, a price-to-earnings ratio of -18.92 and a beta of 0.71. Protalix BioTherapeutics has a 52 week low of $0.82 and a 52 week high of $2.54. The firm’s fifty day moving average is $1.91 and its 200-day moving average is $1.37.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several institutional investors have recently bought and sold shares of PLX. XTX Topco Ltd bought a new stake in Protalix BioTherapeutics in the third quarter valued at approximately $36,000. Cubist Systematic Strategies LLC bought a new position in Protalix BioTherapeutics during the 2nd quarter valued at approximately $37,000. Sanctuary Advisors LLC purchased a new stake in Protalix BioTherapeutics in the third quarter worth $38,000. PFG Investments LLC bought a new stake in Protalix BioTherapeutics in the fourth quarter valued at $39,000. Finally, Virtu Financial LLC bought a new position in shares of Protalix BioTherapeutics in the 3rd quarter worth approximately $44,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.